A股異動 | 眾生藥業漲6% 治療輕型和普通型新冠病毒感染患者創新藥RAY1216片Ⅲ期臨牀試驗全部患者入組
格隆匯1月3日丨眾生藥業(002317.SZ)漲6.37%,報28.71元,總市值234億元。眾生藥業2日公吿,公司控股子公司廣東眾生睿創生物科技有限公司組織開展的一類創新藥物RAY1216片,其用於治療輕型和普通型SARS-CoV-2感染患者的隨機、雙盲、安慰劑對照III期臨牀研究,已經按臨牀方案要求,完成全部病例數入組。

Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.